Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease

AbstractThere is a closely relationship between the development and progression of nonalcoholic fatty liver disease (NAFLD) or metabolic associated fatty liver disease (MAFLD) and obesity and diabetes. NAFLD fibrosis scores should be routinely used to rule out patients with advanced fibrosis. High scores may help identify patients at higher risk of all causes andliverrelated morbidity and mortality. The aim of this study was to investigate the association between exenatide and fibrosis scores. The effect of exenatide treatment on fibrosis scores was evaluated in type 2 diabetes mellitus (DM) patients with MAFLD. Evaluation was made of 50 patients with type 2 DM and MAFLD. The NFS, FIB4 and APRI scores were calculated before and after 6 months of treatment. After 6 months of exenatide treatment, the NFS and APRI scores were determined to have decreased significantly. Exenatide was observed to control blood glucose, reduce body weight and improve fibrosis scores in MAFLD patients with type 2 diabetes.

Download Full-text

Role of folate in nonalcoholic fatty liver disease

Canadian Journal of Physiology and Pharmacology ◽

10.1139/cjpp-2016-0681 ◽

2017 ◽

Vol 95 (10) ◽

pp. 1141-1148 ◽

Cited By ~ 20

Author(s):

Victoria Sid ◽

Yaw L. Siow ◽

Karmin O

Keyword(s):

Type 2 Diabetes ◽

Liver Disease ◽

Fatty Liver ◽

Nonalcoholic Fatty Liver Disease ◽

Fatty Liver Disease ◽

Serum Folate ◽

Nonalcoholic Fatty Liver ◽

Obesity And Diabetes

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of chronic liver conditions that are characterized by steatosis, inflammation, fibrosis, and liver injury. The global prevalence of NAFLD is rapidly increasing in proportion to the rising incidence of obesity and type 2 diabetes. Because NAFLD is a multifaceted disorder with many underlying metabolic abnormalities, currently, there is no pharmacological agent that is therapeutically approved for the treatment of this disease. Folate is a water-soluble B vitamin that plays an essential role in one-carbon transfer reactions involved in nucleic acid biosynthesis, methylation reactions, and sulfur-containing amino acid metabolism. The liver is the primary organ responsible for storage and metabolism of folates. Low serum folate levels have been observed in patients with obesity and diabetes. It has been reported that a low level of endogenous folates in rodents perturbs folate-dependent one-carbon metabolism, and may be associated with development of metabolic diseases such as NAFLD. This review highlights the biological role of folate in the progression of NAFLD and its associated metabolic complications including obesity and type 2 diabetes. Understanding the role of folate in metabolic disease may position this vitamin as a potential therapeutic for NAFLD.

Download Full-text

Prevalence of non-alcoholic fatty liver disease in type-2 diabetes mellitus patients

International Journal of Research in Medical Sciences ◽

10.18203/2320-6012.ijrms20181290 ◽

2018 ◽

Vol 6 (4) ◽

pp. 1322 ◽

Cited By ~ 1

Author(s):

Hardik Patel ◽

Yadav Narain Verma

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Diabetic Patients ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Background: Non-alcoholic fatty liver disease (NAFLD) is a common chronic condition of which diabetic fatty liver accounts for a large proportion, with 50 to 75% of the subjects demonstrating fat in the liver on ultrasound. As a result of epidemic increase in diabetes mellitus, hypertension, obesity and hyperlipidemia, the prevalence of NAFLD is increasing worldwide.Methods: A study was conducted on a total 100 type-2 diabetes mellitus patients attending Geetanjali Medical College and Hospital, Udaipur, Rajasthan. Patients with known chronic liver disease and history of alcohol intake were excluded. These patients were evaluated by abdominal ultrasonography to determine the presence of fatty liver. They were divided into fatty liver group and non-fatty liver group; and were further evaluated by measurement of body mass index, Central obesity, HbA1c and lipid profile. The data obtained was analyzed using SPSS version 20.0.Results: Of the 100 diabetic patients enrolled in this study, 64 (64%) presented with NAFLD. The highest prevalence of NAFLD was recorded in the age group of 50-59 years at 37.5%. The prevalence rate among males (65.62%) was higher than for females (34.38%). A comprised NAFLD patients (64%) and Non-NAFLD patients (34%).Conclusions: This study revealed that the NAFLD is a vital part of cluster of abnormalities such as dysglycemia, dyslipidemia, hypertension and obesity. Age and duration of diabetes are also important contributing factors in occurrence of NAFLD.

Download Full-text

Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan

Diagnostics ◽

10.3390/diagnostics10030159 ◽

2020 ◽

Vol 10 (3) ◽

pp. 159 ◽

Cited By ~ 3

Author(s):

Tran Thi Khanh Tuong ◽

Dang Khoa Tran ◽

Pham Quang Thien Phu ◽

Tong Nguyen Diem Hong ◽

Thien Chu Dinh ◽

...

Keyword(s):

Type 2 Diabetes ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Liver Steatosis ◽

Diabetic Patients ◽

Advanced Fibrosis ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Patients with type 2 diabetes mellitus (T2DM) are at increased risk of non-alcoholic fatty liver disease (NAFLD) and might eventually progress to advanced fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Recommendations on whether to screen for NAFLD in diabetic patients remains conflicted between major guidelines. Transient elastography using FibroScan with CAP (controlled attenuation parameter) can assess both liver steatosis and fibrosis simultaneously. This paper took a new look at the prevalence of NAFLD and the severity of fibrosis among T2DM patients in Vietnam. The study was conducted using a cross-sectional design in T2DM adults who attended Dai Phuoc Ho Chi Minh Polyclinic and Polyclinic of Pham Ngoc Thach University of Medicine. Liver steatosis and fibrosis was assessed by FibroScan. NAFLD was diagnosed if CAP > 233 dB/m (steatosis > 5%). Data were analyzed using STATA 12 software program. We found that a total of 307 type 2 diabetic patients qualified for the study’s criteria. The prevalence of NAFLD in T2DM patients based on FibroScan was 73.3%. Rates of mild, moderate and severe steatosis were 20.5%, 21.8% and 30.9%, respectively. The prevalence of significant fibrosis (≥ F2), advanced fibrosis (≥ F3) and cirrhosis (F4) was 13.0%, 5.9% and 3.6%, respectively. On multivariate analysis, aspartate aminotransferase (AST) (OR: 1.067; 95% CI: 1.017–1.119; p = 0.008) and platelet levels (OR: 0.985; 95% CI: 0.972–0.999; p = 0.034) were independent of risk factors of advanced fibrosis. Thus, our study supports screening for NAFLD and for evaluating the severity of liver fibrosis in T2DM patients.

Download Full-text

Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation

Endocrine Metabolic & Immune Disorders - Drug Targets ◽

10.2174/1871530318666180716100543 ◽

2019 ◽

Vol 19 (2) ◽

pp. 185-188 ◽

Cited By ~ 6

Author(s):

Ghada Abdelmoemen ◽

Samy Abdelkader Khodeir ◽

Ahmed Nabil Zaki ◽

Maha Kassab ◽

Sabry Abou-Saif ◽

...

Keyword(s):

Type 2 Diabetes ◽

Liver Disease ◽

Fatty Liver ◽

Nonalcoholic Fatty Liver Disease ◽

Lipid Accumulation ◽

Fatty Liver Disease ◽

Diabetic Patients ◽

Nonalcoholic Fatty Liver ◽

Hepatic Lipid Accumulation

Background & Aims: Insulin resistance is the real determinant of both Nonalcoholic fatty liver disease (NAFLD) and diabetes, and can facilitate the accumulation of triglycerides in the liver. Overexpression of hepassocin (HPS) increased the accumulation of hepatic fat and NAFLD activity scores (NAS) in mice. The aim of this study was to investigate the relationship between hepassocin and steatosis of the liver in diabetic patients with or without NAFLD in humans. Methods: The study enrolled 60 patients plus 20 healthy controls that were divided into 4 groups: Group I: included 20 patients who were diagnosed as diabetes mellitus type 2, Group II: included 20 patients who were diagnosed as nonalcoholic fatty liver disease (NAFLD), Group III: included 20 patients who were diagnosed as diabetes type 2 and NAFLD, and Group IV (control group): included 20 healthy person or controls who were matched in age and sex with patients group. All patients and controls were subjected to full history taking, thorough clinical examination, laboratory investigations including measurement of serum hepassocin in peripheral blood by ELISA technique. Results: There was a significant overexpression of serum hepassocin in patients with type 2 diabetes and NAFLD patients (Group 3) more than diabetic patients (Group 1) and even more than non-alcoholic fatty liver disease (Group 2). Conclusion: This study provides evidence that increased HPS may facilitate increased hepatic lipid accumulation with NAFLD and type 2 diabetes.

Download Full-text

RISK FACTORS ASSOCIATED WITH TYPE 2 DIABETES MELLITUS AND THE FREQUENCY OF NAFLD AFFECTED PATIENTS

International Journal of Advanced Research ◽

10.21474/ijar01/13093 ◽

2021 ◽

Vol 9 (07) ◽

pp. 11-15

Author(s):

Rehana Ahmed ◽

◽

Mahrukh Hamed ◽

Nebela Khan ◽

Saurabh Singh ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Nonalcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Diabetics have a higher risk of developing nonalcoholic fatty liver disease (NAFLD) and associated complications than the general population. The purpose of this study was to determine the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in patients with type 2 diabetes, as well as the demographic, metabolic, and biochemical features associated with it. Material and methods: This was a prospective, observational, descriptive (cross-sectional), and non-interventional research on a cohort of type 2 diabetes mellitus patients conducted in a hospital setting. Over the course of 18 months, this study was done (August 2019 to March 2021). Results: A total of 100 patients were enrolled, with 63 (63%) being Females and 64 (37%) being men. Age, BMI, and diabetes duration all had statistically significant positive correlations with the prevalence of nonalcoholic fatty liver disease. Overall prevalence of NAFLD was 63 percent (63/100). In this investigation, gender, age > 48, BMI > 25 kg/m2, and diabetes mellitus duration > 10 years were all risk variables linked with the existence of NAFLD (p=0.0002). Conclusion:Present study highlighted the significant burden of Non-Alcoholic Fatty Liver Disease in cohort of type -2 Diabetes Mellitus. About half of the subjects had NAFLD (63%). In present study high BMI, and duration of diabetes > 10 years were positively correlated with NAFLD.

Download Full-text